In a joint statement with Cipla, Roche India said that the second batch of the Covid-19 drug will be made available by mid-June. The cost of each dose, the statement said, will be ₹59,750. Drugs majors Roche India and Cipla announced on Monday the first batch of Roche’s antibody cocktail drug is now available in India for the treatment of mild to moderate Covid-19 in patients, who are at high risk. The cocktail drug (Casirivimab and Imdevimab), priced at ₹59,750 per dose, received emergency use authorisation (EUA) by the Central Drugs Standard Control Organisation (CDSCO) on May 5, for use against the coronavirus disease (Covid-19). “The first batch is now available in India, while the second one will be made available by mid-June. In total, these can potentially benefit 200,000 pat...
Read More
Wednesday, November 20
CovidAdda.com | Find Covid-19 related information, Beds, Oxygen, Plasma, Food
Lets Save Every Single Life
CovidAdda.com | Find Covid-19 related information, Beds, Oxygen, Plasma, Food
Lets Save Every Single Life
Trending Now
- Free Covid Treatment for BPL People
- Revised Covid-19 Guidelines for Adults – January 2022
- Omicron is here, what to do now?
- Pet Boarding Centers in Bangalore
- What is Omicron Variant?
- Home Quarantine Guidelines for Covid-2022
- Fever Hospitals in Bangalore
- Free Vaccination Drive for Helpers in Bellandur, Sarjapur Road & Harlur Road, Bangalore
- Black Fungus FAQs
- Roche India launches first batch of antibody cocktail for treating Covid-19